Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
2016 · OncoImmunology · 294 citations
https://doi.org/10.1080/2162402x.2016.1261779
J
Jing Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
268
Papers
9.4K
Citations
47
h-index
115
i10-index
Jing Li is an academic researcher from Guangzhou University of Chinese Medicine. The author has contributed to research in topics: Immune Cell Function and Interaction & Cancer Immunotherapy and Biomarkers & CAR-T cell therapy research. The author has an h-index of 47, co-authored 228 publications.
ORCID: 0000-0002-9285-9423Papers by this author
worksTargeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway
2021 · Journal of Hematology & Oncology · 90 citations
https://doi.org/10.1186/s13045-021-01168-1
A human autoimmune organoid model reveals IL-7 function in coeliac disease
2024 · Nature · 55 citations
https://doi.org/10.1038/s41586-024-07716-2
Interleukin-23 receptor signaling impairs the stability and function of colonic regulatory T cells
2023 · Cell Reports · 42 citations
https://doi.org/10.1016/j.celrep.2023.112128
γδ T cell antigen receptor polyspecificity enables T cell responses to a broad range of immune challenges
2024 · Proceedings of the National Academy of Sciences · 28 citations
https://doi.org/10.1073/pnas.2315592121
Collagen scaffold microenvironments modulate cell lineage commitment for differentiation of bone marrow cells into regulatory dendritic cells
2017 · Scientific Reports · 16 citations
https://doi.org/10.1038/srep42049
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat